PHASE 1/2 STUDY OF NOVEL HER2-TARGETING, TLR7/8 IMMUNE-STIMULATING ANTIBODY CONJUGATE (ISAC) BDC-1001 WITH OR WITHOUT IMMUNE CHECKPOINT INHIBITOR IN PATIENTS WITH ADVANCED HER2-EXPRESSING SOLID TUMORS Sharma, M., Dumbrava, E., Carvajal, R., Catenacci, D., Emens, L., Hanna, G., Juric, D., Kang, Y., Lee, J., Lee, K., Li, B., Moore, K., Pegram, M., Pohlmann, P., Rasco, D., Spira, A., Tan, A., Wang, D., Ackerman, S., LeBlanc, H., Dornan, D., Kowanetz, M., Alonso, M., Perez, E., Perez, E. BMJ PUBLISHING GROUP. 2020: A244

View details for DOI 10.1136/jitc-2020-SITC2020.0401

View details for Web of Science ID 000616665300390